I don't think credibility has anything to do with it. The PPS is where it is right now because the management still has credibility. If no one thought that Lympro would generate some sort of revenue soon™, the additional 1b shares would have caused a panic. There is a lot of confidence that Lympro will be able to at least subsidize the company's activities. Today it was down a bit, but after it rose what? Almost 20%? There are lot of catalysts coming up that will keep the share price at lease sustained the very least in my opinion.
The "fluff" PRs aren't really fluff at all. They are communicating with their shareholders. AMBS is not exactly a widely held company. I think they are going above and beyond to keep the current share holders in the loop to keep confidence levels up with them. At some point a catalyst is going to attract new blood. The ODDs may do it and revenue to keep company afloat could really attract attention. The current state of the company does not merit an almost $400m market cap, however the catalysts coming up sure as heck may.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links